A Phase 1 Dose Escalation and Expanded Cohort Study of P-MUC1C-ALLO1 in Adult Subjects With Advanced or Metastatic Solid Tumors

This is an open label, multi-center Phase 1 study that will follow a 3 + 3 design of dose-escalating cohorts of single and multiple doses of P-MUC1C-ALLO1 to determine a Recommended Phase 2 Dose (RP2D). P-MUC1C-ALLO1 is an allogeneic chimeric antigen receptor (CAR) T cell therapy designed to target cancer cells expressing Mucin1 cell surface associated C-Terminal (MUC1-C) antigen. Additional participants will be treated with P-MUC1C-ALLO1 at the determined RP2D.

Following enrollment, subjects will be treated with P-MUC1C-ALLO1 and will undergo serial measurements of safety, tolerability and response. Rimiducid may be administered as indicated.


Poseida Therapeutics

Status of enrollment

Open to accrual

Ages Eligible for Study

Adults aged 18 years and up

Genders Eligible for Study

Males or Females

Disease indication

Solid tumor expressing Mucin1

Principal Investigator

David Oh, MD, PhD


Chris De Leon
[email protected]

Additional study eligibility details can be found at UCSF Clinical Trials.